Cheap as chips, page-20

Some interesting points. Thank you for sharing!

-Larger pharmaceutical companies are on the sidelines, but now with binoculars not with a blind eye
-In 2019 and 2020, and beyond, youre going to see more clinical date, more science and more delivery mechanisms
-They werent ready to take the risk until the smaller guys figured it out. Now they have, a lot of companies that were on the sidelines, pre Epidiolex approval, have jumped in the space. Weather thats biotech start ups or major pharma who are developing their own research programmes
-Pharma companies want to see more and more therapeutic value, through approvals for more indications, before they begin to make major acquisitions, investments or joint ventures
-The FDA is vocal about a bright future for pharmaceutical CBD

**-In addition, people are making medical claims that their products are able to cure everything from acne to cancer, which raises a big red flag for the FDA ** Except for Botanix! haha strange!!!! Except for hopefully BOT and true medical research. ** DYOR